Discounted Cash Flow (DCF) Analysis Levered
BioNano Genomics, Inc. WT EXP 08212... (BNGOW)
$0.05
+0.01 (+19.90%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 12 | 10.13 | 8.50 | 17.98 | 27.80 | 37.15 | 49.63 | 66.31 | 88.60 | 118.37 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -19.94 | -29.53 | -38.31 | -71.93 | -124.82 | -130.55 | -174.43 | -233.05 | -311.38 | -416.03 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -0.33 | -0.06 | -0.14 | -0.30 | -0.47 | -0.63 | -0.84 | -1.12 | -1.49 | -1.99 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -20.28 | -29.59 | -38.46 | -72.23 | -125.28 | -131.18 | -175.26 | -234.17 | -312.87 | -418.02 |
Weighted Average Cost Of Capital
| Share price | $ 0.05 |
|---|---|
| Beta | 0.000 |
| Diluted Shares Outstanding | - |
| Cost of Debt | |
| Tax Rate | -1.44 |
| After-tax Cost of Debt | 2.55% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 3.608 |
| Total Debt | 11.67 |
| Total Equity | - |
| Total Capital | - |
| Debt Weighting | - |
| Equity Weighting | - |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 12 | 10.13 | 8.50 | 17.98 | 27.80 | 37.15 | 49.63 | 66.31 | 88.60 | 118.37 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -19.94 | -29.53 | -38.31 | -71.93 | -124.82 | -130.55 | -174.43 | -233.05 | -311.38 | -416.03 |
| Capital Expenditure | -0.33 | -0.06 | -0.14 | -0.30 | -0.47 | -0.63 | -0.84 | -1.12 | -1.49 | -1.99 |
| Free Cash Flow | -20.28 | -29.59 | -38.46 | -72.23 | -125.28 | -131.18 | -175.26 | -234.17 | -312.87 | -418.02 |
| WACC | ||||||||||
| PV LFCF | - | - | - | - | - | |||||
| SUM PV LFCF | - |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | - |
| Free cash flow (t + 1) | -426.38 |
| Terminal Value | - |
| Present Value of Terminal Value | - |
Intrinsic Value
| Enterprise Value | - |
|---|---|
| Net Debt | 6.58 |
| Equity Value | - |
| Shares Outstanding | - |
| Equity Value Per Share | - |